Taysha Gene Therapies reported a net loss of $46.6 million for the second quarter ended June 30, 2026, widening from a $26.9 million loss in the same period of 2025. The company’s earnings per share (EPS) came in at $(0.13), missing the analyst consensus estimate of $(0.12) by 8.33 percent. This represents a 44.44 percent increase in losses compared to $(0.09) per share in the prior year period, driven by accelerated research and development spending on its lead candidate TSHA-102 for Rett syndrome.

The widening deficit reflects significant investment in advancing TSHA-102 toward potential regulatory approval. Research and development expenses rose $18.5 million year-over-year to $38.6 million, fueled by process performance qualification (PPQ) activities and enrollment in the REVEAL pivotal and ASPIRE trials. General and administrative expenses also increased by $3.5 million to $12.1 million, attributed to higher compensation costs and consulting fees associated with commercial launch-readiness initiatives. Despite the operational losses, Taysha strengthened its balance sheet through a $230 million follow-on equity offering, securing a cash position of $455.4 million that management expects will fund operations into the second half of 2028.

Clinical and Corporate Progress

Taysha completed dosing in both its REVEAL pivotal trial (N=17) and the ASPIRE trial (N=4) during the quarter, marking a critical milestone in its development strategy. The REVEAL trial evaluates a single intrathecal administration of high-dose TSHA-102 in females aged 6 to under 22 years with Rett syndrome, with a primary endpoint assessing developmental milestone gains. The ASPIRE trial focuses on safety and preliminary efficacy in younger patients aged 2 to under 4 years. Data from these trials supports a planned Biologics License Application (BLA) submission, with top-line results from the six-month interim analysis expected in the first half of 2027.

Safety data remains favorable, with no severe treatment-related serious adverse events or dose-limiting toxicities observed across 33 patients treated in the REVEAL Phase 1/2, pivotal, and ASPIRE trials as of the August 2026 data cutoff. Longer-term follow-up data presented at the 2026 International Rett Syndrome Foundation meeting demonstrated broad, multi-domain functional gains that deepened over time, regardless of patient age or disease severity.

Financial Position and Outlook

The company’s cash and cash equivalents stood at $455.4 million as of June 30, 2026, up from $319.8 million at the end of 2025, reflecting the gross proceeds from the June 2026 public offering which included the full exercise of underwriters’ options. Total assets increased to $470.4 million from $343.3 million, while total liabilities decreased slightly to $83.2 million from $96.4 million, primarily due to reductions in operating lease liabilities. Stockholders’ equity expanded to $387.3 million, supported by additional paid-in capital from the financing activity.

Looking ahead, Taysha anticipates completing the BLA-enabling PPQ campaign in the fourth quarter of 2026. The company has also expanded its strategic partnership with Catalent to secure commercial manufacturing supply at Catalent’s FDA-licensed facility in Maryland, ensuring readiness for potential launch. Payer research indicates strong support for TSHA-102’s value proposition, citing its transformative potential and one-time administration model as key drivers for reimbursement. Management plans to discuss BLA submission pathways with the U.S. Food and Drug Administration following the interim analysis, targeting regulatory feedback in early 2027.

Taysha Gene Therapies and Catalent have expanded their strategic partnership by signing a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy for Rett syndrome. The agreement designates Catalent as Taysha’s primary commercial manufacturer, securing long-term capacity and a scalable supply framework to support a potential launch following U.S. Food and Drug Administration (FDA) approval. This move addresses critical infrastructure needs for bringing the therapy to market for patients with this rare neurodevelopmental disorder.

The partnership builds on a relationship established in 2020 that has supported the development of TSHA-102. Catalent will provide Good Manufacturing Practice (GMP) manufacturing and commercial supply at its FDA-licensed commercial gene therapy facility in Harmans, Maryland. The facility leverages Catalent’s experience across more than 90 gene therapy programs, including multiple commercial products.

Sean P. Nolan, Chairman and Chief Executive Officer of Taysha, stated that establishing long-term commercial manufacturing capacity is a critical component of the company’s launch readiness strategy. He noted that Catalent’s deep gene therapy expertise and proven commercial manufacturing capabilities make them an ideal partner. Nolan added that with Biologics License Application (BLA)-enabling Process Performance Qualification activities underway, Taysha believes it has established the necessary manufacturing foundation to support expected demand.

David McErlane, Biologics Group President for Catalent, emphasized the company’s priority to support innovators redefining possibilities for patients with rare diseases. He highlighted that the partnership combines deep adeno-associated virus (AAV) expertise with a shared commitment to advancing a potential therapy for Rett syndrome, a condition with significant unmet need.

Partnership Details

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene. It primarily affects females and is characterized by loss of communication and hand function, regression of development, motor impairment, seizures, and intellectual disabilities. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. The condition is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

What the Numbers Show

The expansion of the partnership from development to commercial manufacturing signals a transition toward late-stage regulatory milestones. With BLA-enabling activities underway, the focus has shifted from clinical trial supply to preparing for market entry. The reliance on Catalent’s existing FDA-licensed facility in Maryland reduces the capital expenditure and timeline risks associated with building new manufacturing infrastructure, allowing Taysha to concentrate resources on regulatory approval and commercialization strategy.